03.20.24 -- Shakespeare's Guide To RNA Therapeutics GMP Principles

In the following article, I offer some of the biggest tips and tricks experts provided during a panel discussion on the challenges of navigating GMP principles in the RNA space today — with a little bit of help from Shakespeare himself. 

Once a month, I compile the ATMP articles and industry updates I think are most worthy of your time into an unconventional roundup article. As we recently celebrated St. Patrick's Day, I took my latest inspiration from some traditional Irish drinking songs. Please read responsibly. 

Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma. 

To address today's challenges and other headwinds, pharma/biotech organizations and CMO/CDMO partners need to re-evaluate and improve externalized operating models. Consider further investing in digitalizing collaboration processes as part of operational excellence and digital transformation road map efforts. 

In this clip, Sanofi’s Greg Troiano kickstarts our discussion on some of the advances he’s seen in the supply chain for linear mRNA-LNP products, both in terms of supply availability and supplier capability.

We spoke to three long-standing members of BioPhorum’s Risk and Business Continuity Workstream about their companies’ approaches to risk management, supply chain continuity, and what they learned from the pandemic.